We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
15
3 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
2003
Active, not recruiting
3
20.0%
Completed
8
53.3%
Recruiting
2
13.3%
Terminated
No approval data available
- The gout therapeutics pipeline has expanded significantly with over 20 companies developing 25+ novel drugs across various clinical stages, addressing critical unmet needs in gout management. - Recent clinical milestones include Atom Therapeutics' ABP-671 achieving its primary endpoint in Phase IIb/III trials and multiple FDA Fast Track designations for promising candidates. - Key pipeline therapies utilize diverse mechanisms of action including URAT1 inhibitors, xanthine oxidase inhibitors, and inflammasome inhibitors to target different aspects of gout pathophysiology. - The market is positioned for sustained growth driven by rising disease prevalence, increasing awareness, and strong demand for effective long-term management solutions.
